Navigating Healthcare Deals and Challenges with Geoffrey Cockrell, Partner at McGuireWoods LLP 7-12-24
In this episode, Scott Becker speaks with Geoffrey Cockrell, Partner at McGuireWoods LLP, about the current downturn in healthcare provider deals, challenges in private equity, and the headwinds impacting the industry. Cockrell provides insights into balance sheet problems, regulatory pressures, and the importance of strategic healthcare investments.
Insights on Interest Rates, Private Credit, and Healthcare Transactions with Matt Wolf, Healthcare Senior Analyst and National Health Care Business Valuation Leader at RSM 7-11-24
In this episode, Scott Becker interviews Matt Wolf, Healthcare Senior Analyst and National Health Care Business Valuation Leader at RSM. They discuss the latest trends in interest rates and CPI, the evolving private credit and lending environment, and key trends in healthcare transactions, including the impact on pharma, life sciences, and provider deals.
Doug McMillon & Walmart: 8 Quick Points 7-11-24
In this episode, Scott Becker discusses eight key insights about Walmart and its CEO, Doug McMillan. Highlights include Walmart’s impressive $640 billion in revenue, McMillan’s remarkable rise from a high school employee to CEO, and the company’s successful integration of e-commerce. Tune in for a concise overview of Walmart’s market position and leadership under McMillan.
8 Stories We Are Following Today 7-11-24
In this episode, Scott Becker covers the latest market surges and subsequent retreats, discusses the mixed signals from inflation trends, provides updates on major players like Walmart, Tesla, Rivian, and Lucid Motors, and highlights the current state of healthcare deals.
Tesla, Rivian, and Lucid Motors: The Good, the Bad, and the Ugly – Seven Key Points 7-10-24
In this episode, Scott Becker delves into the current state of Tesla, Rivian, and Lucid Motors, highlighting their sales figures, stock performance, and financial challenges. He explores Rivian’s recent lifeline from Volkswagen and discusses the market dynamics shaping the future of these electric vehicle companies.
7 Private Equity Stories We Are Following 7-10-24
In this episode, Scott Becker discusses seven notable private equity stories, including Maxwell Street Capital’s recent strides, KKR and Blackstone’s market performance, and the latest investment by Dental Investment Alliance. He also highlights Pitchbook’s new pharma services report, Iron Path Capital’s $273 million fund, and Peter Thiel’s Piloter Technologies’ impressive year-to-date growth.
14 Stories We Are Following Today 7-10-24
This episode, Scott Becker provides a comprehensive overview of current market trends, including updates on NVIDIA, Tesla, and Treasury yields. He also discusses key investments in the logistics and dental sectors, and highlights notable industry reports and events. Tune in for a deep dive into the latest in private equity and business.
Private Equity Trends in Healthcare: A Conversation with Holly Buckley, Chair of Health Care at McGuireWoods LLP 7-9-24
In this episode, Scott Becker discusses the latest healthcare private equity trends with Holly Buckley, Chair of Healthcare at McGuireWoods LLP. Holly shares insights on provider transactions, biotech, medical devices, revenue cycle management, and the evolving digital health landscape.
10 Stories We Are Following Today 7-9-24
In this episode, Scott Becker delves into 10 key stories, including the Fed’s balancing act with unemployment and inflation, the political contributions of top CEOs, and the evolving landscape of Ivy League social clubs. Also featured are insights into Best Buy’s transformation, UnitedHealthcare’s financial performance, and notable trends in the retail sector. Tune in for […]
Healthcare Private Equity Trends – 3 Key Sectors 7-9-24
In this episode, Scott Becker discusses the latest trends in healthcare transactions, focusing on practice and bolt-on transactions, medical device deals, and the revitalized biotech sector. He highlights the challenges and opportunities within these areas, including regulatory scrutiny and high-profile deals, offering a comprehensive overview of the current healthcare private equity landscape.